Skip to main content

Table 2 Changes in lipid profile of eligible patients before and after treatment

From: Baicalin reduces blood lipids and inflammation in patients with coronary artery disease and rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial

 

Baicalin (n = 166)

Placebo (n = 165)

Baseline

Post treatment

Baseline

Post treatment

TG (mmol/L)

2.77 ± 1.26

1.12 ± 0.36 *

2.83 ± 1.35

1.87 ± 0.46 *#

TC (mmol/L)

4.62 ± 1.53

2.87 ± 1.23 *

4.75 ± 1.62

3.22 ± 1.07 *#

HDL-C (mmol/L)

0.96 ± 0.35

1.38 ± 0.41 *

1.02 ± 0.24

1.16 ± 0.32 *#

LDL-C (mmol/L)

2.84 ± 0.71

1.73 ± 0.52 *

2.91 ± 0.83

2.42 ± 0.57 *#

ApoA1 (g/L)

1.13 ± 0.22

1.31 ± 0.41 *

1.16 ± 0.27

1.23 ± 0.29 *#

ApoB100 (g/L)

0.83 ± 0.21

0.43 ± 0.11 *

0.86 ± 0.25

0.67 ± 0.23 *#

  1. Values are mean ± SD. *p < 0.05 compared to baseline within the same group; #p < 0.05 compared at the same time point between two groups. TG triglycerides, TC total cholesterol, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, ApoA 1 , apolipoprotein A1, ApoB 100 apolipoprotein B100